ASCO Gastrointestinal Cancers Symposium

Regorafenib Plus TAS-102 Demonstrates Clinically Meaningful Disease Control in mCRC

January 27, 2020

The combination of regorafenib plus an oral fluoropyrimidine, TAS-102, as third-line treatment in patients with metastatic colorectal cancer, achieved a clinically meaningful disease control rate in the phase I dose-escalation trial REMETY, according to data presented at the 2020 Gastrointestinal Cancers Symposium.

Consistent Treatment Benefit With Ramucirumab Across Staging in HCC

January 27, 2020

Better rates of overall survival were observed in patients with intermediate-stage hepatocellular carcinoma who had an elevated baseline alpha-fetoprotein level when ramucirumab was used as second-line therapy after sorafenib compared with second-line placebo. These improvements occurred irrespective of patients' Barcelona Clinic Liver Cancer stage and were based on results of a pooled analysis of the phase III REACH and REACH-2 trials

Microsatellite Instability Serves as a Predictive Biomarker of Response to Pembrolizumab

January 26, 2020

Joseph Chao, MD, discusses the importance of assessing the microsatellite instability (MSI) status in patients with advanced gastric/gastroesophageal junction cancer based on findings from a comparative analysis of KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062.

Lenvatinib Plus Nivolumab Demonstrates Antitumor Activity in Unresectable HCC

January 26, 2020

Lenvatinib in combination with nivolumab demonstrated promising antitumor activity in patients with unresectable hepatocellular carcinoma with no new safety signals reported.

Patients With HCC Experience Better OS With Anticancer Procedure After Lenvatinib

January 25, 2020

Frontline lenvatinib followed by an anticancer procedure resulted in prolonged overall survival in patients with unresectable hepatocellular carcinoma when compared against sorafenib, according to results of a post hoc analysis of the REFLECT trial reported at the 2020 GI Cancers Symposium.

PARP Added to Chemotherapy Results in Positive Responses for Pancreatic Cancer

January 25, 2020

Antitumor activity in patients with germline BRCA/PALB2-mutant pancreatic ductal adenocarcinoma was reported with the chemotherapy doublet of gemcitabine plus cisplatin with or without the addition of veliparib, according to data presented at the 2020 Gastrointestinal Cancers Symposium.

Adding Dietary Supplements to Treatment Impacts Outcomes in Unresectable Pancreatic Cancer

January 25, 2020

In an interview with Targeted Oncology, Vincent Chung, MD, discussed the findings from the pilot trial evaluating the addition of dietary supplements to combination chemotherapy in patients with unresectable pancreatic cancer. He also highlighted the importance of these findings and the next steps necessary to evaluate the role of supplements in pancreatic cancer further.

Durable Responses Achieved With Triplet Combination in Gastric Cancer

January 25, 2020

Promising antitumor activity with durable responses were demonstrated with the combination of nivolumab and ramucirumab plus paclitaxel in a phase II study of patients with advanced gastric cancer, which wsa presented at the 2020 Gastrointestinal Cancers Symposium. Among patients treated with the combination, the objective response rate was 37.2%, and all responders had a partial response.

Ipilimumab Plus Cabozantinib and Nivolumab Increased Responses in Advanced HCC

January 25, 2020

The addition of ipilimumab with the combination cabozantinib and nivolumab led to higher response rates, as well as progression-free survival and overall survival in patients with advanced hepatocellular carcinoma compared with the doublet combination alone, according to a presentation at the 2020 GI Cancers Symposium, held January 23-25, in San Francisco, California.

Pembrolizumab Improves OS in Patients With High PD-L1 Gastric Cancers

January 24, 2020

Overall survival was meaningfully improved with treatment of pembrolizumab in first and later lines for patients with advanced gastric/gastroesophageal junction cancer with a high number of PD-L1–expressing cells in the tumor, lymphocytes, and macrophages compared with chemotherapy.